# OnCo record alk-resistance-mutation (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/alk-resistance-mutation/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "alk-resistance-mutation" ;
  schema:name "ALK kinase-domain resistance mutation (G1202R and the rest)"@en ;
  schema:alternateName "ALK resistance mutation"@en, "G1202R"@en, "ALK G1202R"@en, "L1196M"@en, "ALK secondary mutation"@en, "solvent front mutation"@en ;
  schema:description "After a lung cancer stops responding to an ALK-blocking tablet, finding a change inside the ALK protein itself is good news: it means the cancer still depends on ALK, and a later-generation tablet is likely to work. Finding none means the opposite."@en ;
  schema:url <https://onco.cc/biomarkers/alk-resistance-mutation/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/2159-8290.CD-16-0596>, <https://doi.org/10.1200/JCO.18.02236>, <https://doi.org/10.1056/NEJMoa1508887> ;
  onco:tag "biomarker", "resistance" ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:pathways <https://onco.cc/pathways/resistance-routes-map/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/clonal-evolution/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/cross-resistance/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/biopsy/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/>, <https://onco.cc/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/>, <https://onco.cc/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/> .
